News

Despite FDA ruling, compounded GLP-1s are still giving Novo and Lilly headaches on the market

When the FDA took Novo Nordisk and Eli Lilly’s GLP-1 medications off of the drug shortage list, the move should have been a ...

Weight-loss drug Wegovy launches in South Africa

The launch marked Danish drugmaker Novo Nordisk's debut on the continent, ramping up competition with rival Eli Lilly.

Analysis-Wall Street sees new obesity pills as priced near Wegovy and Zepbound

U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...

GoodRx begins selling Novo Nordisk GLP-1s for cash price

GoodRx (GDRX) is joining in on the GLP-1 action with an announcement on Monday that it will begin selling both of Novo Nordisk's (NVO) GLP-1 drugs, Ozempic for diabetes and Wegovy for weight loss, at ...

Novo Nordisk offers diabetes drug Ozempic for less than half the price for cash-paying U.S. patients

Patients can pay $499 in cash per month for three dose sizes of Ozempic through the company's direct-to-consumer pharmacy and GoodRx, among other platforms.